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Abstract: BACKGROUND Migraine is a multifactorial neurovascular disorder, which affects about 12%
of the general population. In episodic migraine, the visual cortex revealed abnormal processing, most
likely due to decreased preactivation level. Transcranial direct current stimulation (tDCS) is able to
modify cortical excitability and might result in an alleviation of migraine occurrence if used repeti-
tively. OBJECTIVE To test the hypothesis that self-administered anodal tDCS over the visual cortex
significantly decreases the number of monthly migraine days in episodic migraine. MATERIALS AND
METHODS The study was single-blind, randomized, and sham-controlled. Inclusion criteria were age
18-80 years and an ICHD-3 diagnosis of episodic migraine. Exclusion criteria were pregnancy, presence
of a neurodegenerative disorder, a contraindication against MRI examinations, and less than two mi-
graine days during the 28-day baseline period. Patients in whom the baseline period suggested chronic
migraine were excluded. After baseline, participants applied daily either verum (anodal-1 mA to 20 min)
or sham tDCS (anodal-1 mA to 30 sec) at Oz (reference Cz electrode) for 28 days. Headache diaries were
used to record the number of migraine days at baseline, during the stimulation period, and during four
subsequent 28-day periods. RESULTS Twenty-eight patients were included; two were excluded after the
baseline period because less than two migraine days occurred; three were excluded because their headache
diaries suggested the diagnosis of chronic migraine. Twenty-three datasets were taken for further analysis.
Compared to sham tDCS (n = 12), verum tDCS (n = 11) resulted in a lower number of migraine days
(p = 0.010) across all follow-up periods. We found no significant change in total headache days (p =
0.165), anxiety (p = 0.884), or depression scores (p = 0.535). No serious adverse events occurred; minor
side effects were similar in both groups. CONCLUSIONS This study provides Class II evidence that
self-administered anodal tDCS over the visual cortex in episodic migraine results in a significantly lower
number of monthly migraine days. However, it has neither an immediate nor a long-term effect.
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Abstract 
Background: Migraine is a multifactorial neurovascular disorder which affects about 12 % of the general 
population. In episodic migraine, the visual cortex revealed abnormal processing, most likely due to 
decreased pre-activation level. Transcranial direct current stimulation (tDCS) is able to modify cortical 
excitability and might result in an alleviation of migraine occurrence if used repetitively.  
Objective: To test the hypothesis that self-administered anodal tDCS over the visual cortex significantly 
decreases the number of monthly migraine days in episodic migraine. 
Methods: The study was single-blind, randomised, and sham-controlled. Inclusion criteria were age 18-
80 years and an ICHD-3 diagnosis of episodic migraine. Exclusion criteria were pregnancy, presence of 
a neurodegenerative disorder, a contraindication against MRI examinations, and less than two migraine 
days during the 28-day baseline period. Patients in whom the baseline period suggested chronic 
migraine were excluded. After baseline, participants applied daily either verum (anodal-1mA-20min) or 
sham tDCS (anodal-1mA-30sec) at Oz (reference Cz electrode) for 28 days. Headache diaries were used 
to record the number of migraine days at baseline, during the stimulation period, and during four 
subsequent 28-day periods.  
Results: Twenty-eight patients were included; two were excluded after the baseline period because less 
than two migraine days occurred; three were excluded because their headache diaries suggested the 
diagnosis of chronic migraine. Twenty-three datasets were taken for further analysis. Compared to sham 
tDCS (n=12), verum tDCS (n=11) resulted in a lower number of migraine days (P=0.010) across all follow-
up periods. We found no significant change in total headache days (P=0.165), anxiety (P=0.884), or 
depression scores (P=0.535). No serious adverse events occurred; minor side effects were similar in 
both groups. 
Conclusions: This study provides Class II evidence that self-administered anodal tDCS over the visual 
cortex in episodic migraine results in a significantly lower number of monthly migraine days. However, 
it has neither an immediate nor a long-term effect. 
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Introduction 
Brains of migraine patients process sensory information differently(1). Photo-, and Phonophobia are 
common both during(2, 3) and between attacks(4, 5). Interictally, many migraineurs do not habituate 
to repeated somatosensory(6), visual(7), acoustic(8), and painful stimuli(9). 
Several studies investigated the cortical responsivity in order to elucidate underlying mechanisms. In 
episodic migraine (EM), the abnormal processing in the visual cortex is thought to reflect a decreased 
pre-activation level due to an insufficient thalamo-cortical drive(10, 11). In chronic migraine (CM), 
however, some studies indicate hyperexcitability of visual and somatosensory cortices(12, 13). Even 
though not all studies confirm these findings and alternative interpretations have been proposed(14), 
there is evidence for altered cortical information processing over the migraine cycle. 
Transcranial direct current stimulation (tDCS) can modify cortical excitability(15-18) presumably 
through hyperpolarisation or subthreshold depolarisation of neurones depending on current 
direction(19). Consequently, tDCS seems to lend itself to the treatment of functional disorders 
characterised by altered brain excitability, as present in migraine. This appears all the more attractive 
since this approach has no serious side effects, while most preventive migraine pharmacotherapies have 
an unfavourable efficacy/adverse effect profile(20). 
The suitability of tDCS for the treatment of migraine was examined in several studies applying tDCS to 
the occipital cortex(21-24), the primary motor cortex(25-27), or the dorsolateral prefrontal cortex(26, 
28) of migraine patients. In most – not all(23) – of these open-label(21, 27, 28) and sham-controlled 
trials(22, 24), a significant reduction of migraine days was achieved. In addition, tDCS restored 
habituation to repeated visual stimuli in patients with EM(21, 29). 
While in some studies anodal stimulation was used(21, 25-27), in others cathodal stimulation was 
chosen(22-24), and one study combined both approaches(28). The difference between these 
techniques is noteworthy as anodal stimulation is generally viewed as increasing and cathodal 
stimulation as decreasing cortical excitability(16-18), although not everybody responds in the predicted 
way(30, 31). 
Considering the cited findings, one may speculate that anodal tDCS is best suited for EM and cathodal 
stimulation for CM, as these disorders may be characterised by cortical hypo- and hyperexcitability, 
respectively(10-13). This hypothesis has not yet been confirmed and not in every study undertaken so 
far, EM and CM were distinguished. 
In this study, we decided to tailor the stimulation pattern to the supposed cortical pre-activation level 
of the participants’ visual cortices by treating EM patients with (presumably activating) anodal tDCS over 
the occipital cortex. We analysed the effect of a 28-day treatment period on migraine/headache days 
and disability, but also on anxiety and depression that are often comorbid with migraine(32). 
We also decided to study self-administered tDCS, which may be challenging. Laypersons who mount 
electrodes themselves might indeed be unable to position them correctly despite adequate training and 
thereby impede correct stimulation, since minor deviations of the electrode position can impact both 
the current path and the induced electric field(33, 34), and may prevent the electric field from 
concentrating under the active electrode(35). 
In addition, we assessed the persistence of the stimulation effect up to four months post-treatment. So 
far, most studies did not evaluate the duration of the clinical tDCS effects in migraine, except for one 
study that found a significant reduction in migraine attacks up to eight weeks after the end of the 
stimulation(36). 
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We hypothesized that, compared to sham stimulation, anodal tDCS would result in a long-lasting 
reduction of migraine days in patients suffering from EM. To our knowledge, no randomised, sham 
controlled study (with a longitudinal design) has yet addressed this research question. Thus, the 
novelties of this tDCS study in episodic migraine prevention are application of an excitatory protocol 
over the visual cortex, self-administration by the patients and investigation of long-term effects. 
Methods 
Participants and inclusion/exclusion criteria 
All participants gave their informed consent and the local ethics committee approved the study. 
Inclusion criteria were age between 18 and 80 years and a diagnosis of “EM without aura” or of “EM 
with and without aura” according to the ICHD-3 criteria(3). All headache diagnoses had been made by 
a neurologist. 
Exclusion criteria were pregnancy, presence of a neurodegenerative disorder, and contraindication 
against an MRI examination. Patients who had less than two migraine days during the 28-day baseline 
period were excluded. In addition, we validated the diagnosis of EM based on the baseline period; 
participants who had 15 or more headache days and eight or more migraine days were excluded 
because these symptoms were more consistent with a diagnosis of CM. 
Headache diary 
Participants kept headache diaries(37) throughout the study and recorded occurrence, duration, quality 
and intensity of headache attacks, as well as acute medication intake and accompanying features.  
Migraine days were identified and distinguished from days with other headache types based on the 
headache diary using the criteria proposed by Tassorelli and co-workers(38). A migraine day was defined 
as day with a headache that lasts at least four hours and fulfils one of the conditions. (i) Criteria C and 
D for migraine without aura according to the ICHD-3 are met; (ii) criteria B and C for migraine with aura 
are met, (iii) criteria for probable migraine are met; (iv) the headache is treated successfully with a 
triptan. We defined moderate to severe pain as pain ratings of four and above on a numerical rating 
scale ranging from zero to 10, zero indicating the absence of pain and 10 the strongest imaginable pain. 
Completeness of the headache diaries was evaluated on a monthly basis. If headache days had been 
recorded incompletely, data for that period were considered missing; we did not impute. 
Study design 
This monocentric, single-blind, randomised, and sham-controlled trial was conducted at the University 
Hospital Zurich. Sample size was not calculated before the study, because no pilot data were available 
for the chosen study design. Participants were randomised to receive either verum or sham tDCS; group 
allocation was concealed from all participants and the principal investigator until the end of the study. 
We used a block randomisation technique with block sizes of ten (comprising 5 verum and 5 sham per 
block). Two authors, KB and JA enrolled and assigned participants to interventions; they also had 
generated the random allocation sequence. 
Throughout the study period, participants recorded headache days in calendars. To allow statistical 
analysis, we subdivided the diary entries into six subsequent 28-day periods, which will be referred to 
as baseline period, T1, T2, T3, T4, and T5. The prospective 28-day baseline period ended with the 
baseline visit. The next day, the 28-day stimulation period (referred to as T1) was launched. After that, 
patients recorded their headaches during four subsequent 28-days periods (T2, T3, T4, and T5; see 
figure 1). 
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In addition, all participants were examined in three presential visits: baseline visit, follow-up visit 1 
(FUP1), and follow-up visit 2 (FUP2); see figure 1. The baseline visit marked the end of the baseline 
period and the onset of T1; the FUP 1 was scheduled shortly after the stimulation period (T1) and FUP2 
took place after T5, about six months post-baseline. At each of these visits, multiparametric MRI 
examinations were performed; these data will be published separately. The trial was registered at 
ClinicalTrials.gov (Identifier: NCT03237754). 
tDCS 
tDCS was performed using a one-channel stimulator and standard rubber tDCS electrodes provided by 
the manufacturer (DC-STIMULATOR PLUS, NeuroConn, Ilmenau, Germany). Participants applied anodal 
stimulation over the visual cortex (see Figure 2 A for the tDCS montage). The active electrode was placed 
at Oz (electrode size 5*7 cm2), while the reference electrode was placed at Cz (electrode size 10*10 
cm2). Oz is located at the inion, while the Cz is located at the intersection between a sagittal line from 
the nasion to the inion and a coronal line connecting the tragus of both ears. We chose a more focal 
electrode to maximize the current density over the visual cortex (current density of the active electrode 
is 0.029 mA/cm2) and a large reference electrode to minimize current density at the Cz area (current 
density of the reference electrode is 0.01 mA/cm2). Thus, the large reference electrode was functionally 
ineffective(39).  
At the baseline visit the investigator explained the electrode placement to the participants and 
instructed them to first place the rubber electrodes in the sponge pads (NeuroConn, Ilmenau, Germany) 
and to soak them in saline water. The electrodes were kept in place by standard elastic rubber straps. 
tDCS was performed at a 1 mA intensity for 20 minutes per session. We chose 1mA in order to minimize 
the possible discomfort of the patients during the stimulation, and encourage future studies comparing 
the effects of 1mA and 2mA. Sham stimulation also had 1mA intensity but was maintained for only 30 
seconds; during the remaining 1170 seconds only intermittent impedance checks occurred. We 
computed the normalized electric field distribution using a realistic finite element head model(40) 
implemented in the Simnibs 2.1 toolbox (https://simnibs.github.io/simnibs)(41). As expected, the 
predicted electric field is strongest in the vicinity of the active electrode placed over the visual cortex 
(see Figure 2 B). Participants applied verum or sham tDCS at home once daily over a four-week period 
and logged sessions in a stimulation diary. 
Efficacy endpoints 
The primary endpoint was the overall estimated marginal mean change from baseline in the number of 
monthly migraine days across T2 to T5. A secondary endpoint was the overall marginal mean change 
from baseline in the number of monthly headache days, medication days, migraine intensity, and 
headache intensity across T2 to T5.  
Further secondary endpoints were the estimated marginal mean changes from baseline in monthly 
migraine days during T1, T2, T3, T4, and T5. In addition, we calculated change from baseline in monthly 
headache and medication days as well as in average intensity of migraine and headache days during T4; 
we decided to calculate differences between sham and anodal stimulation during T4 as between-group 
differences were largest during that period (see results). Finally, we calculated the percentage of 
patients whose number of monthly migraine and headache days was halved in T4 compared to baseline 
(50%-responder rate). 
Further secondary endpoints were changes from baseline in the score of the hospital anxiety and 
depression scale (HADS-A and HADS-D, respectively) as well as the migraine disability assessment scale 
(MIDAS) at the first and second follow-up visit (FUP1 and FUP2). 
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Safety 
All participants were asked to record side effects of the intervention. In particular, we asked for tingling, 
pain, nausea, and fatigue. Adverse events that occurred during and up to four weeks after the 
stimulation period were registered (in paper form) as well. No additional exams (e.g. vital signs, 
neurological examination, etc.) were performed at the follow-up visits. 
Statistical analysis 
The analyses were conducted in the modified intention-to-treat population, which consisted of all 
participants who had completed the stimulation period (T1). 
We analysed the primary endpoint – i.e., the overall mean change from baseline in the monthly number 
of migraine days – using a mixed effects model. Categorical fixed effects were group assignment (anodal 
versus sham stimulation). Continuous fixed effects were the baseline frequency of migraine days, the 
number of stimulation days, the score in the HADS-D, as well as the stimulation days-by-baseline 
migraine frequency interaction. We included the depression score as covariate because there is 
evidence of depression altering cortical excitability(42-45). Normal distribution of dependent variables 
was assessed before analysis using the Shapiro Wilk test. 
Some participants applied tDCS for more or less than 28 days. To account for this imbalance, we included 
the number of stimulation days as covariate into the statistical model. To prevent inconsistencies caused 
by different lengths of T1, the reported frequencies were normalised to migraine and headache days 
per 28 days. 
In order to track changes in migraine frequency over the study period, we counted migraine days during 
baseline as well as T1, T2, T3, T4, and T5 and estimated marginal changes separately for each period, by 
conducting a mixed effect model for each period analogously to the above-mentioned approach. 
Secondary endpoints analysing changes from baseline in total headache days and medication days as 
well as changes in intensity in T4 were analysed analogously to the primary endpoint. Instead of the 
baseline number of migraine days, baseline values of the relative variable were added as continuous 
fixed effect.  
Likewise, we assessed changes in the average score in the HADS-A, HADS-D, and MIDAS using mixed 
effects models. Since the follow-up visits were postponed in some cases, we included the length of the 
delays as covariate into the mixed effect model. 
Serial testing served as gatekeeping strategy to prevent the increase of the overall type I error by 
multiple testing(46). Statistical testing of the secondary endpoints was not pursued if the stimulation 
effect analysed in the primary endpoint did not have a significant impact on migraine days. We did not 
correct for multiple testing; thus, the analyses of the secondary endpoints need to be considered 
exploratory. 
Group differences were assessed with two-sided t-tests, ANOVA, and Chi-squared test. We used IBM 
SPSS statistics version 25 for the calculations; significance level was set at 0.05. 
Classification of evidence 
We used the AAN Classification of Evidence Matrix to determine the class of evidence(47). The study 
was designed to answer the following research question: Does tDCS using anodal stimulation for EM 
influence the number of monthly migraine days? 
Data availability 
The data collected and analysed for the current study are available from the corresponding author on 
reasonable request. 
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Results 
We screened 28 participants with EM. Two patients were excluded after the baseline period because 
less than two migraine days occurred; three patients were excluded because they had recorded in their 
headache diaries 15 or more headache days and eight or more migraine days during the baseline period 
and were thus more likely to suffer from CM than EM. The trial was halted due to recruitment 
difficulties. The characteristics of the remaining 23 participants are listed in Table 1. Fourteen 
participants had reported at least one aura during the study period (14/23, 61%); of these seven (50%) 
had received sham tDCS stimulation. One patient did not complete the headache diary during T2; apart 
from that, there were no missing data. 
While we planned a stimulation period of 28 days, some patients used their stimulation device for less 
or more than 28 days (on average 29 ± 2 days). The average number of stimulation days was higher in 
the tDCS groups than in the sham group (tDCS 30 ± 3 days, sham 28 ± 0.5 days; P=0.044).  
Efficacy endpoints 
Across all patients, the estimated marginal mean change in monthly migraine days across T2 to T5 was 
-1.7 ± 0.5 days (95%-CI -2.6 – -0.7) in the anodal tDCS group and 0.2 ± 0.4 days (95%-CI -0.7 – 1.1) in the 
sham tDCS group; a positive number implies an increase in migraine days. The overall between-group 
difference across T2 to T5 was 1.9 ± 0.7 days (95% confidence interval: 0.5 – 3.3; P=0.010). Changes 
from baseline in migraine days were normally distributed in all periods T2 to T5 according to the Shapiro 
Wilk test (P=0.497, P=0.633, P=0.439, and P=0.682, respectively). Thus, our data show that anodal tDCS 
over the visual cortex significantly decreases the number of migraine days across a 5-month period. 
When adding a factor to the model that differentiates participants who had at least one aura during the 
study period from those without an aura, this variable was not found to have a significant influence on 
changes in migraine days (P=0.114). 
Considering each period (T1 to T5) separately, changes in migraine days at T4 (P=0.033) were significant 
and there was a trend for significance at T3 (P=0.081). However, there was no significant difference in 
changes between the two groups during stimulation (T1; P=0.944), as well as in T2 (P=0.497), and T5 
(P=0.631); see Figure 3 for graphical depiction.  
During T4, four patients in the tDCS group (4/11, 36.3%) and two patients in the sham group (2/12, 
16.7%) had a reduction of at least 50% in the number of migraine days (50%-responders); the difference 
was not significant (P=0.371). 
Mean changes in monthly headache days, medication days, and both migraine and headache intensity 
across T2 to T5 are summarised in Table 2. Normal distribution was confirmed for changes from baseline 
in headache days (P=0.216, P=0.843, P=0.513, and P=0.323), medication days (P=0.095, P=0.520, 
P=0.672, and P=0.090), migraine intensity (P=0.083, P=0.433, P=0.209, and P>0.999), and headache 
intensity (P=0.478, P=0.388, P=0.978, and P=0.238) for all periods T2 to T5. 
The estimated marginal mean change in monthly headache days between baseline and T4 was -3.3 ± 
0.8 days (95%-CI -4.9 – -1.7) in the tDCS group and -0.7 ± 0.7 days (95%-CI -2.2 – 0.9) in the sham group; 
the difference between the groups was statistically significant (P=0.041). However, changes in 
medication days, migraine intensity, and headache intensity did not differ between the groups during 
T4 (P=0.118, P=0.831, and P=0.454, respectively).  
Secondary endpoints evaluating the estimated marginal changes from baseline in the scores in the 
HADS-D, HADS-A, and MIDAS at the first and the second follow-up visit are summarised in Table 3. The 
average delay between the baseline visit and the first follow-up visit was 50 ± 8 days; the second follow-
up visit took place 218 ± 64 days after baseline visit.  
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We were unable to build a mixed effects model to analyse whether the stimulation had an influence on 
aura, because changes from baseline to T2, T3, T4, and T5 in days with an aura were not normally 
distributed (P=0.013, P<0.001, P<0.001, P<0.001). Using an ANOVA (which is more robust to 
distributional deviations from normality) and including into the analysis only participants who had 
reported at least one aura during the whole study period, we did not find differences in the changes 
from baseline in the number of auras in T1, T2, T3, T4, and T5 between sham and verum tDCS (P=0.135, 
P=0.359, P=0.797, P=0.180, and P=0.907, respectively). 
Safety 
Participants were asked to note adverse events experienced during stimulation. Tingling was reported 
by eight patients in the sham group and six in the verum group (P=0.680). Nausea occurred in one 
patient in the sham group and three in the verum group (P=0.317). Pain was felt by five participants 
receiving sham stimulation and four participants in the anodal group (P>0.999). Finally, fatigue was 
reported by four patients in the sham group and six in the verum group (P=0.414). 
In addition, in the sham group, one patient reported pain in their right ear, one patient recalled a 
migraine attack in close temporal relationship with stimulation, and one patient noted a depressed 
mood during stimulation. In the verum tDCS group, one patient reported a migraine attack to have 
occurred during stimulation, and one participant recalled temporary pain in the right half of his face 
during stimulation. No serious adverse event occurred. 
Discussion 
Preventive treatment with anodal tDCS over occipital cortex resulted in a significantly lower number of 
migraine days after a 28-day stimulation period. The difference between the groups was 1.9 ± 0.7 days. 
Even though the proportion of 50%-responders was higher in the verum tDCS group than in the sham 
group; the difference was not significant. Yet, in our opinion, reducing an average of five migraine days 
per month by two days can be clinically meaningful. 
The changes in migraine days in our study were smaller than in a previous study by Viganò and co-
workers who also applied anodal stimulation the visual cortex(21). In EM, they reported a reduction in 
migraine days from 15 to eight per two months during an eight-week stimulation period; they 
performed two stimulation sessions per week. However, comparability is limited because in their study, 
no sham group had been included and statistical analysis was not corrected for baseline characteristics. 
Furthermore, they did not report how migraine days were distinguished from other headache types. 
In the present study, the influence of tDCS on migraine days was not discernible during stimulation (T1) 
but set in belatedly. It seems that, at the group level, the tDCS effect is building up in the first months 
after the intervention, and reaches its the maximum at T4. Previous studies have also confirmed such a 
lagging effect but have reported varying delays between the baseline examination and measurable 
changes(21, 25). However, the moment in which the effect occurs does not seem to depend solely on 
the time passed since the start of the stimulation. The number of sessions may be more important as 
only repeated stimulations have been reported to induce sustained changes in cortical excitability. That 
is, changes in cortical excitability induced by one session of tDCS were found to last only several 
minutes(19), but tDCS repeated daily led to a summation of the stimulation effects on evoked 
potentials(48).  
The low number of 50%-responders is probably explained by a considerable inter-individual variability 
in response to tDCS(30, 31). Thus, it would be helpful if therapeutic responses could be predicted. We 
suggest investigating in future studies whether improvement of habituation heralds therapeutic 
success; previous research had shown that that (i) in prophylactic treatment with topiramate, 
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improvement of habituation correlates with therapeutic success and that (ii) tDCS of the visual cortex 
can improve habituation(21, 49).  
Interestingly, we recorded a slight increase in migraine days in the sham group during T1 and T2 (see 
Figure 3). The reason for this finding is unknown. However, previous research indicates that, in clinical 
trials, the quality of entries in headache diaries ameliorates over time(51). Hence, an increasing quality 
of the entries during T1 and T2 might have led to the identification of an increasing number of headache 
days as migraine days. Consequently, we must suspect a systematic error that does not affect 
generalisability of the results because both groups were affected. 
Although negative expectancies have been found to reduce the effect of tDCS(52), we do not believe 
that the paradoxical increase in migraine days in the sham group was due to participants being able to 
guess group allocation. This is because, first, the reported side-effects did not differ between the groups 
and, second, the impact on migraine did not differ between the groups during the stimulation period.  
Every secondary endpoint analysed in this study was negative. We only found tendencies towards a 
stronger reduction of depressive symptoms in the verum tDCS group and towards differences in the 
MIDAS score between the two groups at FUP1 (P=0.052). However, there were no changes in the total 
number of headache days, the number of medication days, the average intensity of migraine and 
headache days, as well as the scores of HADS-A. These findings suggest that tDCS reduces the number 
of migraine days but changes neither the attacks itself nor comorbidities. 
While the MIDAS score did not differ significantly between the two groups at baseline, there was a trend 
towards higher values in the sham group (P=0.093). The reason for this finding is unclear. We suspect 
random fluctuation because, at the first follow-up visit, the two groups had approximated – the MIDAS 
score had decreased in the sham tDCS group and increased in the verum tDCS group. At the second 
follow-up visit (FUP2), we found a decrease in both groups, which indicates that, in absolute values, the 
MIDAS score was lower in the verum tDCS group. This latter finding is not unexpected, as the number 
of migraine days decreased after the stimulation period. 
Contrasting with our results, previous studies using various tDCS protocols have reported a reduction of 
the number headache days, the number of medication days and pain intensity, and attack duration, and 
an increased quality of life in migraine patients(22-24, 26, 27, 36). Moreover, in these studies the 
beneficial effects occurred earlier than in our sample. Unlike ours, these studies had methodological 
shortcomings as the statistical models were not corrected for baseline characteristics. Finally, we cannot 
exclude that to some extent, our differing results may be attributable to the self-administration of the 
treatment, as minor deviations of the electrode position can impact current path, the induced electric 
field, and the concentration of the electric field under the active electrode.(33-35) 
No between-group difference persisted four months post-treatment (T5), suggesting a fleeting 
stimulation effect; the average pain intensity of individual attacks was not influenced. The only study 
investigating the long-term effect of tDCS on migraine attacks found its influence subsiding slowly as 
well and detected no effect 12 weeks after stimulation(36). It is possible that tDCS temporarily defies 
the tendency towards an altered cortical excitability – yet, the tendency persists and prevails after some 
time. Thus, this technique may tackle the pathophysiological cascade of migraine attacks in an advanced 
stage, but not at its start. 
This study did not raise safety concerns against tDCS as no severe adverse events occurred. The number 
of patients reporting side effects of the stimulation did not differ significantly between the groups, 
suggesting that patients probably could not distinguish verum stimulation from sham tDCS. 
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These encouraging results emphasise that tDCS can be an effective alternative when pharmacological 
preventive treatment is contraindicated, ineffective or disliked by the patient. A favourable side effect 
profile may increase adherence as fear of intolerance often prevents patients from taking prophylactic 
treatment.(54) This view is supported by studies reporting adherence rates of the Cefaly device that 
largely exceed those of pharmacological treatment approaches(55, 56). 
The strengths of this study are the very long follow-up period and the randomised, controlled, and 
blinded assessment of the intervention. In addition, the data suggest that treatment successes can be 
achieved when patients apply the stimulation independently at home.  
Some limitations must be noted. The classification of individual attacks was based on the headache 
diary; non-migraine days were not classified. In personal interviews, more headache attacks might have 
been identified as migraine attacks. In addition, we did not correct for multiple testing. In order to 
prevent the increase of the overall type I error by multiple testing, we used a gatekeeping strategy; the 
secondary endpoints are thus to be considered exploratory. Finally, we also aimed to include chronic 
migraine patients in a second arm with a different stimulus paradigm. However, the study was halted 
due to recruitment issues. 
Conclusion 
A 28-day self-administered transcranial direct current stimulation protocol is safe and results in a 
significantly lower number of migraine days than sham stimulation over five months, especially at three 
and four months after the intervention. It might be an alternative or a complementary intervention to 
pharmacological treatments.  
However, the self-administered anodal tDCS over the visual cortex, as applied in this study, has no 
immediate effects and does not lead to between-group differences extending beyond four months. 
Consequently, it would be of interest to investigate in future studies if longer stimulation periods are 
able to provide longer-lasting therapeutic benefit.  
In addition, our data suggest that tDCS has no effect on headaches other than migraine or on comorbid 
anxiety or depressive symptoms. 
Classification of Evidence 
This study provides Class II evidence that anodal tDCS over the visual cortex in episodic migraine results 
in a significantly lower number of monthly migraine days. 
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Table 1. Baseline characteristics of the participants; MIDAS  – Migraine Disability Assessment, HADS-A – anxiety subscale of the 
hospital anxiety and depression scale, HADS-D – depression subscale of the hospital anxiety and depression scale 
Characteristic 
Sham 
(N = 12) 
tDCS 
(N = 11) P value 
Age – years 34 ± 10 41 ± 15 0.211 
Female sex – no. (%) 12 (100%) 10 (90.1%) 0.478 
Average number of migraine days during baseline 6 ± 3 5 ± 2 0.118 
Average number of all headache days during baseline 8 ± 2 7 ± 3 0.239 
Average number of medication days during baseline 6 ± 3 4 ± 3 0.192 
Average baseline intensity migraine days during baseline – 1 to 10/10 5 ± 2 6 ± 1 0.199 
Average baseline intensity of headache days during baseline – 1 to 
10/10 
5 ± 1 6 ± 1 
0.178 
Average baseline total MIDAS score 35 ± 23 19 ± 20 0.093 
Average baseline HADS-A score 6 ± 3 7 ± 4 0.601 
Average baseline HADS-D score 4 ± 4 4 ± 2 0.805 
 
Table 2. Estimated marginal mean changes from across T2 to T5 (i.e. four times 28-days); positive values imply an increase 
 Sham tDCS P value 
Estimated marginal mean change from baseline in monthly migraine days 
0.2 ± 0.4 -1.7 ± 0.5 
0.010 
Estimated marginal mean change from baseline in monthly headache days -0.5 ± 0.5 -1.9 ± 0.5 0.102 
Estimated marginal mean change from baseline in the average pain level of 
migraine attacks 
0.0 ± 0.2 -0.1 ± 0.2 0.711 
Estimated marginal mean change from baseline in the average pain level of 
headache attacks 
0.0 ± 0.2 -0.3 ± 0.2 0.348 
Estimated marginal mean change from baseline in monthly medication days -1.0 ± 0.4 -0.9 ± 0.4 0.957 
 
Table 3. Secondary endpoints evaluating estimated marginal mean changes from baseline at the first follow-up visit (FUP1, 50 
± 8 days after the baseline visit) and the second follow-up visit (FUP2, 218 ± 64 days after the baseline visit); positive values 
indicate an increase; MIDAS  – Migraine Disability Assessment, HADS-A – anxiety subscale of the hospital anxiety and depression 
scale, HADS-D – depression subscale of the hospital anxiety and depression scale 
  Sham tDCS P value 
FUP1 Estimated marginal mean change from baseline in total MIDAS score  
-7.7 ± 4.6 5.9 ± 4.1 
0.052 
 Estimated marginal mean change from baseline in HADS-A score  -0.5 ± 0.7 -0.6 ± 0.7 0.884 
 Estimated marginal mean change from baseline in HADS-D score  -0.2 ± 0.5 -0.7 ± 0.5 0.535 
FUP2 Estimated marginal mean change from baseline in total MIDAS score  -3.7 ± 6.3 -1.8 ± 5.9 0.838 
 Estimated marginal mean change from baseline in HADS-A score  -1.0 ± 1.5 -1.8 ± 1.7 0.480 
 Estimated marginal mean change from baseline in HADS-D score  1.2 ± 0.7 -0.9 ± 0.7 0.064 
 
  





Figure 1. Overview of the study design; we subdivided the study period into six subsequent 28-day periods (baseline period, 
T1, T2, T3, T4, and T5), during which participants recorded headache days in diaries; tDCS was applied during T1; all participants 
were completed the HADS and MIDAS in three presential visits (baseline visit, follow-up visit 1 – FUP1, and follow-up visit 2 – 
FUP2); the baseline visit marked end of the baseline period and onset of treatment period T1; FUP 1 was scheduled shortly 
after the stimulation period (T1) and a FUP2 took place after T5 
  
Baseline T1 T2 T3 T4 T5 
Baseline visit FUP1 FUP2 
28 days tDCS 
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Figure 2 A The tDCS montage: the position of the active electrode over the visual cortex (size, 5 × 7 cm2; current density 0.029 
mA/cm2) and of the reference electrode over the Cz (size, 10 × 10 cm2; current density 0.01 mA/cm2). B The predicted 
distribution of the normalized electric field. As expected, the predicted electric field is strongest under the active electrode 
placed over the visual cortex. 
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Figure 3. Estimated marginal changes from baseline in migraine days for various time points calculated using mixed effect 
models; T1 refers to the 28-day stimulation period, and T2, T3, T4 and T5 refer to four subsequent 28-days follow-up periods; 
mean changes from baseline differ significantly at T4 (P=0.033), there was a trend for significance at T3 (P=0.081) but there 
was no significant difference in changes in migraine days between the two groups during stimulation (T1; P=0.944), T2 
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